Nanotech Investing Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
Nanotech Investing Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Nanotech Investing Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia
LaFleur Minerals Provides Update on PEA for the Restart of Beacon Gold Mill Sourcing Material from Its Swanson Gold Deposit, Val d'Or, Québec
